Confo Therapeutics today announced the appointment of Rob Scott as an Independent Director. Dr. Scott’s career spans 30 years of drug discovery and development leadership in the global pharmaceutical and biotechnology industries, including his last position as Chief Medical Officer, Head of Development at AbbVie.
by eazee-designstudio
The US Food and Drug Administration has granted Breakthrough Device Designation for GTX Medical‘s implantable Go-2 system which was designed to promote the recovery of leg motor functions and neurological control in adults with spinal cord injuries (SCI) and paralysis. The Go-2 System provides Targeted Epidural Spinal Stimulation (TESS) therapy, promoting the recovery of leg motor functions and neurological control. The Company anticipates the first clinical trial for the complete Go-2 system in humans to take place in 2021.
Confo Therapeutics today announced the appointment of Paolo Vicini in the newly-created position of CDO effective June 1, 2020.With two decades of leadership and scientific experience in pharmaceutical research and development, Dr. Vicini will apply his experience in translational and clinical sciences to support the Company as it moves its GPCR modulating small molecules through preclinical studies and into the clinic.
Themis and MSD (trademark of Merck & Co., Inc., Kenilworth, N.J., USA) today announced that the companies have entered into a definitive agreement under which MSD, through a subsidiary, will acquire privately-held Themis. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur, a world-leading European vaccine research institute, and licensed exclusively to Themis for select viral indications.
Themis and ABL Europe, a global Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO), a subsidiary of the French bioindustrial group Institut Mérieux, announced today that they have signed an agreement under which ABL will manufacture Themis’ vaccine candidate in preparation for clinical trials. The vaccine is being developed using a proprietary measles virus vaccine platform technology, which is licensed exclusively to Themis by the world-renowned Institut Pasteur in Paris.
Mr. Hovard, who will serve as the Company’s first independent Director, brings more than 20 years of leadership in the medical device and urology industry. Over the last 20 years, Mr. Hovard has held multiple leadership roles at subsidiaries of Coloplast, a publicly-traded global medical device company. Most recently, he served as the President of Interventional Urology from 2011 to 2019.
Dr. Murphy joins the company with over twenty years of experience in Class I, II, and III medical devices and implantables and has been instrumental in bringing numerous new devices to commercialization. As a member of GTX’ leadership team, Dr. Murphy will be responsible for leading and executing the company’s technology strategy and advancing its neuromodulation product portfolio, which is designed to improve the functional recovery of people with spinal cord injuries (SCI).
Dr. Dukes has amassed over 20 years in leadership roles at large pharmaceutical and biotechnology companies. As Themis transitions towards rapidly ramping up the development of a coronavirus vaccine candidate towards the clinic in response to the global pandemic and being prepared to supply the initial stockpiles of its vaccine, Dr. Dukes’ background will further enhance the range of experience on the Company’s Board.
STipe Therapeutics announced the appointment of seasoned industry experts: “Both Natalie and Richard are highly experienced industry executives who bring a wealth of international drug development and approval expertise to STipe,” said Dr Claus Elsborg Olesen (CEO). “We are developing novel cancer therapies and I look forward to drawing on their extensive experience as we prepare for the selection of a lead candidate for clinical development.”
Wellington Partners today announced a seed investment into newly founded SIRS Therapeutics, Munich, Germany. With the investment, SIRS has secured the joint ownership with Austrian F4 Pharma of all rights on FX06, a fibrin-derived peptide for treatment of patients with acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS), including patients with underlying COVID-19 infection.
